Physician profile
Charles Turnier
NPI 1952370686
$1,883.26
in general payments reported to CMS, 2019-2025
18 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $112 · 2021: $174 · 2022: $295 · 2024: $362 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $590.92 | 2019-2025 | Tezspire, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $260.30 | 2022-2025 | Takhzyro |
| Regeneron Healthcare Solutions, INC. | $257.44 | 2019-2024 | Dupixent |
| Inspire Medical Systems, INC. | $158.36 | 2025 | Inspire |
| Amgen INC. | $121.93 | 2021-2025 | Actimmune |
| Alk-Abello, INC | $110.92 | 2019 | |
| Glaxosmithkline, LLC. | $73.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.09 | 2019-2020 | |
| Pharming Healthcare, INC. | $58.01 | 2019-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $42.45 | 2019 | |
| Grifols USA, LLC | $21.19 | 2019 | |
| Aimmune Therapeutics, INC. | $21.11 | 2020 | |
| Genzyme Corporation | $20.50 | 2019 | |
| Shire North American Group INC | $16.46 | 2019 | |
| Optinose US, INC. | $15.33 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.11 | 2019 | |
| Kaleo, INC. | $14.92 | 2020 | |
| Pfizer INC. | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Turnier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.